South Korea · Delayed Price · Currency is KRW Shaperon Company Description
Shaperon Inc. develops therapies based on GPCR19-inflammasome inhibitor platform and NanoMab antibody platform for immune diseases.
It offers NuGel which blocks the root cause of atopic dermatitis that is in Phase 2 clinical trials; NuDifin that calms wound inflammation and accelerates the regeneration of tissue; NuRalin indicated for atopic dermatitis; NuAreatin for the treatment of alopecia areata.
The company also provides NuCerin, a pill designed to reduce neuroinflammation; NuSepin, which alleviates excessive systemic inflammation; and NuPulin for the treatment of inflammation-driven pulmonary fibrosis.
In addition, it offers Papiliximab, a NanoMab-based bispecific antibody that blocks PD-L1 and CD47 for leukemia treatment; Ovizumab, a tumor-specific immunotherapy; Regtizumab, an anti-tumor immunity; and Rbody, a NanoMabs’ small size which enables the creation of LNP-mRNA therapeutics.
Further, the company provides RumiLua, a cosmeceutical ingredient to help prevent excessive skin responses while supporting the skin’s natural balance and overall condition.
The company was founded in 2008 and is headquartered in Seoul, South Korea.
| Country | South Korea |
| Founded | 2008 |
| Industry | Biological Products, Except Diagnostic Substances |
| CEO | Seung-Yong Seong |
Contact Details
Address: 174-10 Jagok-ro Seoul South Korea | |
| Phone | 82 2 6083 8315 |
| Website | shaperon.com |
Stock Details
| Ticker Symbol | 378800 |
| Exchange | KOSDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | KRW |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Seung-Yong Seong | Chief Executive Officer |
| Gene Yune | Chief Financial Officer |